New Publication: The Indian Pharmaceutical Industry

The Indian pharmaceutical industry has been witnessing significant growth over the past few years and is expected to grow to USD 130 billion in value by the end of 2030.

For a global pharmaceutical company seeking to enter the Indian pharmaceutical market today, the opportunities are exciting, and the potential is tremendous. Several factors attract global pharmaceutical companies to India:

• Low cost of production due to a variety of factors including relatively lower labour costs and raw material cost;
• Big market not only for life saving drugs but also for lifestyle drugs;
• Potential for conducting research and development activities in India – India has more than 300 medical colleges, over 20,000 hospitals;
• Existing manufacturing capability to produce active pharmaceutical ingredients (APIs) as well as intermediates at lower cost while maintaining quality;
• India has a maximum number of USFDA approved plants outside the US;
• Ease of conducting clinical trials and bioavailability and bioequivalence studies due to India’s ability to provide speedier and less expensive trials without compromising quality and due to a vast patient pool.

In this paper we have outlined the entity structures, the tax regime, both direct and indirect, affecting the structuring of Indian operations, the regulatory aspects and the intellectual property issues that affect the pharmaceutical and life sciences industry.

Regards,

Varsha Rajesh, Eshika Phadke, Darren Punnen and Dr.Milind Antani

We hope you find this paper useful.

Please click here to access our paper.

For any help or assistance, please email us on concierge@nishithdesai.com.

Do visit us at www.nishithdesai.com.